2 not yet recruiting, 2 recruiting, 1 active not recruiting. 5 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Not yet recruiting 2, Recruiting 2, Active not recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Overweight , Obesity: new trials by email Literature Review of Overweight , Obesity trials Research Report on Overweight , Obesity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lifestyle Changes, Mushroom Supplementation, and Bupropion to Reduce Adiposity and Cardiometabolic Risk Bupropion 150 mg, Lyophilized powder from edible mushrooms, Lifestyle Management - Cardiometabolic Syndrome, Obesity and Cardiovascular Risk | Phase 3 | Not yet recruiting | Uppsala University | 250 | 2026-10-30 | 2026-09-08 |
| Safety and Analgesic Efficacy of the Biased μ-Opioid Receptor Agonist Tegileridine for Post-Operative Analgesia in Patients Undergoing Bariatric Surgery Tegileridine (tegileridine fumarate injection, IV), Sufentanil - Pain Management, Overweight , Obesity | Phase 3 | Recruiting | The First Hospital of Jilin University | 148 | 2026-10-28 | 2026-11-03 |
| Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity. Semaglutide, Placebo - Type 1 Diabetes, Overweight , Obesity | Phase 2 / Phase 3 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 40 | 2026-10-13 | 2026-10-23 |
| Phase 3 Study of MWN109 Injection in Participants With Overweight or Obesity MWN109 1, MWN109 2, MWN109 3 - Overweight , Obesity | Phase 3 | Not yet recruiting | Shanghai Minwei Biotechnology Co., Ltd | 760 | 2026-09-01 | 2026-08-21 |
| A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1) Zovaglutide dose 1, Zovaglutide dose 2, Placebo - Overweight , Obesity | Phase 3 | Active not recruiting | Beijing QL Biopharmaceutical Co.,Ltd | 755 | 2026-01-16 | 2026-08-03 |
Obesity (5) · Overweight (5) · Agnosia (1) · Diabetes Mellitus, Type 1 (1) · Hyperlipidemias (1) · Hypertension (1) · Metabolic Syndrome (1) · Prediabetic State (1) · Respiratory Aspiration (1) · Sleep Wake Disorders (1)
Body Weight (5) · Nutrition Disorders (5) · Nutritional and Metabolic Diseases (5) · Overnutrition (5) · Pathological Conditions, Signs and Symptoms (5) · Signs and Symptoms (5) · Diabetes Mellitus (2) · Endocrine System Diseases (2) · Glucose Metabolism Disorders (2) · Metabolic Diseases (2) · Autoimmune Diseases (1) · Cardiovascular Diseases (1) · Dyslipidemias (1) · Hyperinsulinism (1) · Immune System Diseases (1)
Bupropion (1) · Saline Solution (1) · Sufentanil (1) · semaglutide (1)
Beijing QL Biopharmaceutical Co.,Ltd (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Shanghai Minwei Biotechnology Co., Ltd (1) · The First Hospital of Jilin University (1) · Uppsala University (1)
China (3) · Canada (1) · Sweden (1)
Jan Eriksson, MD, PhD (1) · Linong Ji, MD (1) · Martin Lundqvist, MD, PhD (1) · Melissa-Rosina Pasqua, MD, PhD (1)